PMID- 24639005
OWN - NLM
STAT- MEDLINE
DCOM- 20160310
LR  - 20220409
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 31
IP  - 4
DP  - 2014 Apr
TI  - Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the 
      management of drug-related adverse events.
PG  - 375-91
LID - 10.1007/s12325-014-0112-1 [doi]
AB  - Pirfenidone is currently the only approved therapy for idiopathic pulmonary 
      fibrosis, following studies demonstrating that treatment reduces the decline in 
      lung function and improves progression-free survival. Although generally well 
      tolerated, a minority of patients discontinue therapy due to gastrointestinal and 
      skin-related adverse events (AEs). This review summarizes recommendations based 
      on existing guidelines, research evidence, and consensus opinions of expert 
      authors, with the aim of providing practicing physicians with the specific 
      clinical information needed to educate the patient and better manage 
      pirfenidone-related AEs with continued pirfenidone treatment. The main 
      recommendations to help prevent and/or mitigate gastrointestinal and skin-related 
      AEs include taking pirfenidone during (or after) a meal, avoiding sun exposure, 
      wearing protective clothing, and applying a broad-spectrum sunscreen with high 
      ultraviolet (UV) A and UVB protection. These measures can help optimize AE 
      management, which is key to maintaining patients on an optimal treatment dose.
FAU - Costabel, Ulrich
AU  - Costabel U
AD  - Department of Pneumology/Allergology, Ruhrlandklinik, University Hospital, 
      University Duisburg-Essen, Essen, Germany, 
      ulrich.costabel@ruhrlandklinik.uk-essen.de.
FAU - Bendstrup, Elisabeth
AU  - Bendstrup E
FAU - Cottin, Vincent
AU  - Cottin V
FAU - Dewint, Pieter
AU  - Dewint P
FAU - Egan, Jim J J
AU  - Egan JJ
FAU - Ferguson, James
AU  - Ferguson J
FAU - Groves, Richard
AU  - Groves R
FAU - Hellstrom, Per M
AU  - Hellstrom PM
FAU - Kreuter, Michael
AU  - Kreuter M
FAU - Maher, Toby M
AU  - Maher TM
FAU - Molina-Molina, Maria
AU  - Molina-Molina M
FAU - Nordlind, Klas
AU  - Nordlind K
FAU - Sarafidis, Alexandre
AU  - Sarafidis A
FAU - Vancheri, Carlo
AU  - Vancheri C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140318
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Pyridones)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - D7NLD2JX7U (pirfenidone)
EIN - Adv Ther. 2014 May;31(5):575-6
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
MH  - Disease Management
MH  - Disease-Free Survival
MH  - *Drug-Related Side Effects and Adverse Reactions/etiology/prevention & control
MH  - Humans
MH  - *Idiopathic Pulmonary Fibrosis/diagnosis/drug therapy
MH  - *Pyridones/administration & dosage/adverse effects
MH  - Respiratory Function Tests/methods
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
PMC - PMC4003341
EDAT- 2014/03/19 06:00
MHDA- 2016/03/11 06:00
PMCR- 2014/03/18
CRDT- 2014/03/19 06:00
PHST- 2014/01/15 00:00 [received]
PHST- 2014/03/19 06:00 [entrez]
PHST- 2014/03/19 06:00 [pubmed]
PHST- 2016/03/11 06:00 [medline]
PHST- 2014/03/18 00:00 [pmc-release]
AID - 112 [pii]
AID - 10.1007/s12325-014-0112-1 [doi]
PST - ppublish
SO  - Adv Ther. 2014 Apr;31(4):375-91. doi: 10.1007/s12325-014-0112-1. Epub 2014 Mar 
      18.